DK3344655T5 - Brug af anti-cd40-antistoffer til behandling af lupus nefritis - Google Patents
Brug af anti-cd40-antistoffer til behandling af lupus nefritis Download PDFInfo
- Publication number
- DK3344655T5 DK3344655T5 DK16763663.8T DK16763663T DK3344655T5 DK 3344655 T5 DK3344655 T5 DK 3344655T5 DK 16763663 T DK16763663 T DK 16763663T DK 3344655 T5 DK3344655 T5 DK 3344655T5
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- treatment
- lupus nephritis
- nephritis
- lupus
- Prior art date
Links
- 208000005777 Lupus Nephritis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212810P | 2015-09-01 | 2015-09-01 | |
| US201562257336P | 2015-11-19 | 2015-11-19 | |
| US201662287587P | 2016-01-27 | 2016-01-27 | |
| PCT/US2016/049558 WO2017040566A1 (en) | 2015-09-01 | 2016-08-31 | Use of anti-cd40 antibodies for treatment of lupus nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3344655T3 DK3344655T3 (da) | 2023-10-09 |
| DK3344655T5 true DK3344655T5 (da) | 2024-10-07 |
Family
ID=56896810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16763663.8T DK3344655T5 (da) | 2015-09-01 | 2016-08-31 | Brug af anti-cd40-antistoffer til behandling af lupus nefritis |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20170058038A1 (enExample) |
| EP (1) | EP3344655B1 (enExample) |
| JP (2) | JP2018529661A (enExample) |
| KR (1) | KR20180039172A (enExample) |
| CN (1) | CN107922501A (enExample) |
| AU (1) | AU2016317028B2 (enExample) |
| BR (1) | BR112018001907A2 (enExample) |
| CA (1) | CA2993996A1 (enExample) |
| CL (1) | CL2018000317A1 (enExample) |
| DK (1) | DK3344655T5 (enExample) |
| ES (1) | ES2969968T3 (enExample) |
| HU (1) | HUE063528T2 (enExample) |
| MX (1) | MX390653B (enExample) |
| PH (1) | PH12018500445B1 (enExample) |
| PL (1) | PL3344655T3 (enExample) |
| WO (1) | WO2017040566A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| IL270596B1 (en) * | 2017-05-25 | 2025-09-01 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant region for use in treating cancer |
| BR112020024078A2 (pt) * | 2018-06-29 | 2021-02-17 | Boehringer Ingelheim International Gmbh | anticorpos anti-cd40 para uso no tratamento de doença autoimune |
| BR112021010414A2 (pt) * | 2018-11-30 | 2021-09-08 | Jiangsu Hengrui Medicine Co., Ltd. | Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas |
| US12274747B2 (en) | 2021-01-28 | 2025-04-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| RU2006141632A (ru) * | 2004-04-27 | 2008-06-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Антагонистические моноклональные анти-cd40-антитела и способы их применения |
| JP5027804B2 (ja) * | 2005-05-26 | 2012-09-19 | シアトル ジェネティクス，インコーポレーテッド | ヒト化抗ｃｄ４０抗体およびその使用方法 |
| CN101426817B (zh) * | 2006-04-21 | 2013-07-10 | 诺华有限公司 | 拮抗性抗-cd40抗体药物组合物 |
| DK3178851T3 (da) * | 2010-03-31 | 2020-07-27 | Boehringer Ingelheim Int | Anti-cd40-antistoffer |
| ES2709654T3 (es) * | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
-
2016
- 2016-08-31 PL PL16763663.8T patent/PL3344655T3/pl unknown
- 2016-08-31 HU HUE16763663A patent/HUE063528T2/hu unknown
- 2016-08-31 WO PCT/US2016/049558 patent/WO2017040566A1/en not_active Ceased
- 2016-08-31 AU AU2016317028A patent/AU2016317028B2/en not_active Ceased
- 2016-08-31 CA CA2993996A patent/CA2993996A1/en active Pending
- 2016-08-31 CN CN201680050230.6A patent/CN107922501A/zh active Pending
- 2016-08-31 ES ES16763663T patent/ES2969968T3/es active Active
- 2016-08-31 PH PH1/2018/500445A patent/PH12018500445B1/en unknown
- 2016-08-31 EP EP16763663.8A patent/EP3344655B1/en active Active
- 2016-08-31 MX MX2018002447A patent/MX390653B/es unknown
- 2016-08-31 DK DK16763663.8T patent/DK3344655T5/da active
- 2016-08-31 BR BR112018001907A patent/BR112018001907A2/pt not_active Application Discontinuation
- 2016-08-31 US US15/252,308 patent/US20170058038A1/en not_active Abandoned
- 2016-08-31 KR KR1020187009176A patent/KR20180039172A/ko not_active Ceased
- 2016-08-31 JP JP2018511144A patent/JP2018529661A/ja active Pending
-
2018
- 2018-02-05 CL CL2018000317A patent/CL2018000317A1/es unknown
- 2018-07-18 US US16/038,536 patent/US20190177420A1/en not_active Abandoned
-
2021
- 2021-08-20 JP JP2021134828A patent/JP2021185169A/ja active Pending
-
2022
- 2022-10-07 US US17/962,099 patent/US20230265203A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021185169A (ja) | 2021-12-09 |
| KR20180039172A (ko) | 2018-04-17 |
| EP3344655A1 (en) | 2018-07-11 |
| AU2016317028B2 (en) | 2021-09-09 |
| CL2018000317A1 (es) | 2018-07-20 |
| JP2018529661A (ja) | 2018-10-11 |
| BR112018001907A2 (pt) | 2018-09-25 |
| PL3344655T3 (pl) | 2024-02-19 |
| AU2016317028A1 (en) | 2018-02-22 |
| US20230265203A1 (en) | 2023-08-24 |
| MX390653B (es) | 2025-03-21 |
| DK3344655T3 (da) | 2023-10-09 |
| US20190177420A1 (en) | 2019-06-13 |
| ES2969968T3 (es) | 2024-05-23 |
| US20170058038A1 (en) | 2017-03-02 |
| CA2993996A1 (en) | 2017-03-09 |
| MX2018002447A (es) | 2018-06-15 |
| HUE063528T2 (hu) | 2024-01-28 |
| PH12018500445B1 (en) | 2022-08-10 |
| PH12018500445A1 (en) | 2018-09-10 |
| WO2017040566A1 (en) | 2017-03-09 |
| CN107922501A (zh) | 2018-04-17 |
| EP3344655B1 (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3193929T3 (da) | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3173092T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
| DK3344655T5 (da) | Brug af anti-cd40-antistoffer til behandling af lupus nefritis | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier |